EligibleTrials

Clinical trials recruiting for Squamous Cell Carcinoma of the Lung

Fewer than 3 recruiting trials found.

2
Recruiting trials
15
US states with sites
3
Countries
0%
Accept healthy volunteers

Phase breakdown

Phase 1 2

Drugs and treatments being studied

InterventionTrials
BCA1011
EVOLVE1041
Pembrolizumab1

Where trials are recruiting (top US states)

StateRecruiting trials
California2
New York2
North Carolina2
Ohio2
Pennsylvania2
Tennessee2
Texas2
Connecticut1
Florida1
Georgia1
Massachusetts1
Michigan1

Top cities

Cleveland, Ohio 2Houston, Texas 2Los Angeles, California 2Nashville, Tennessee 2New York, New York 2Atlanta, Georgia 1Boston, Massachusetts 1Charleston, South Carolina 1Charlotte, North Carolina 1Duarte, California 1

Self-screener

Recruiting trials

Related conditions

Trials recruiting for Squamous Cell Carcinoma of the Lung often also study these conditions. Each links to its own recruiting-trial list.

Lung cancer 2180Colorectal cancer 1359Squamous Cell Carcinoma of Head and Neck 11Pancreatic cancer 870Pancreas Cancer 86Head and Neck Squamous Cell Carcinoma 42Head and Neck Neoplasms 7Esophageal Squamous Cell Carcinoma 14Epithelial Ovarian Cancer 10Cutaneous Squamous Cell Carcinoma 9

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Squamous Cell Carcinoma of the Lung trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.